CONCORDBIO2023-10-012023-12-31 CONCORDBIO2023-10-012023-12-31 CONCORDBIO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member CONCORDBIO2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2023-04-01 2024-03-31 2024-02-08 2024-01-30 INR Lakhs Third quarter 16:35:00 18:00:00 2024-02-08 2024-02-08 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Consolidated 2407965000.00 81874000.00 2489839000.00 473924000.00 232182000.00 -235235000.00 306714000.00 4953000.00 135370000.00 571094000.00 1489002000.00 1000837000.00 0.00 1000837000.00 257994000.00 -2687000.00 255307000.00 0.00 745530000.00 0.00 0.00 0.00 30197000.00 775727000.00 -6487000.00 769240000.00 775727000.00 0.00 769240000.00 0.00 104616000.00 1 7.41 7.41 0.00 0.00 7.41 7.41 Notes to the statement of consolidated unaudited financial results for the quarter and nine months ended December 31, 2023 : 1. The Company's equity shares have been listed on National Stock Exchange ( NSE ) and on BSE Limited ( BSE ) on August 18, 2023 by completing Initial Public Offering through offer for sale of 2,09,25,652 equity shares of face value of Rs. 1 each at an issue price of Rs. 741 per equity share by selling shareholder. 2. The above consolidated unaudited financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 08, 2024. The Statutory Auditors have carried out limited review of the financial results for the quarter and nine months ended on December 31, 2023. 3.The total initial public offer expenses are entirely allocated to the selling shareholders except for the listing fees which has been solely borne by the Parent. 4.The consolidated financial results for the quarter and nine months ended on December 31, 2022 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs. 5.The Company and its joint venture are engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - Operating Segment . Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 6979698000.00 229684000.00 7209382000.00 1288690000.00 452889000.00 -338037000.00 890913000.00 20891000.00 398735000.00 1712551000.00 4426632000.00 2782750000.00 0.00 2782750000.00 698552000.00 9023000.00 707575000.00 0.00 2075175000.00 0.00 0.00 0.00 55694000.00 2130869000.00 -4036000.00 2126833000.00 2130869000.00 0.00 2126833000.00 0.00 104616000.00 1 20.37 20.37 0.00 0.00 20.37 20.37 Other Expenses 571094000.00 Other Expenses 1712551000.00 -6487000.00 -4036000.00 0.00 0.00 0.00 0.00